Mucosal cytotoxic T lymphocyte responses
AssigneeHealth and Human Services, The Government of the United States of America, as Represented by
InventorsJay Berzofsky, Igor Belyakov, Michael Derby, Brian Kelsall, Warren Strober
Life of this patent
Estimating the term…
Abstract
The invention provides methods for induction of an antigen-specific, mucosal cytotoxic T lymphocyte response useful in preventing and treating infections with pathogens that gain entry via a mucosal surface.
Claims69
A method for inducing a protective mucosal cytotoxic T lymphocyte (CTL) response in a mammalian subject comprising contacting a mucosal tissue of the subject with a composition comprising a purified soluble antigen.
(canceled)
A method for inducing a protective mucosal CTL response in a subject, comprising contacting a mucosal tissue of the subject with a composition comprising a soluble antigen, wherein said composition does not comprise an adjuvant.
(canceled)
An immunogenic composition for inducing a protective mucosal CTL response in a subject and adapted for intrarectal administration comprising a purified soluble antigen formulated for intrarectal delivery to the rectum, colon, sigmoid colon, or distal colon.
The immunogenic composition of claim 66, wherein the protein or peptide is an HIV V3 loop or T cell-binding peptide fragment thereof.
Dependencies are inferred from the claim text.